The therapeutic role of this combination is focused on providing symptomatic relief across acute domains. The formulation is intended for the temporary relief of various minor aches and pains and is commonly applied across conditions presenting with acute episodes of discomfort.

This medicine is applied in managing acute headache episodes, the pain of migraine attacks, elevated body temperature (fever), muscular aches, minor joint discomfort, toothache, and cyclical menstrual cramps. It is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed. “It is commonly used when short-term symptomatic assistance is needed, helping patients cope more steadily with difficult episodes.” The overall benefit is supportive relief that assists with maintaining functional stability during symptomatic phases.

---

Quick Fact: Relief for Acute Discomfort

Symptom Domain	Primary Therapeutic Benefit
Acute Headaches	Easing pain that interferes with daily functioning.
Fever & Aches	Concurrent reduction of elevated temperature and systemic discomfort.
Musculoskeletal Pain	Supportive relief for episodic aches like cramps and muscle strain.

Regulatory References

1. NIH DailyMed Label for Acetaminophen, Aspirin, and Caffeine

Who Can and Cannot Use Аскофен-П? — Official Regulatory Information

The eligibility profile for this combination medicine (Acetaminophen, Acetylsalicylic Acid, Caffeine) is strictly defined by regulatory documents, distinguishing permitted use from absolute contraindications and restrictions.

Contraindicated Populations

Use is contraindicated in patients with a known hypersensitivity to any component or to any non-steroidal anti-inflammatory drug (NSAID). The medicine must not be used by individuals with active peptic ulcers, gastrointestinal hemorrhage, or severe, uncontrolled hepatic, renal, or heart failure. Individuals with underlying blood clotting disorders are also prohibited from use.

Age and Physiological Status Restrictions

• Pediatric Use: The Acetylsalicylic Acid (ASA) component makes this medicine contraindicated or not recommended for children and adolescents under 16 years due to the risk of Reye's syndrome, particularly during viral illness.
• Pregnancy: The medicine is contraindicated from 20 weeks gestation onward due to the risk of fetal harm (ductus arteriosus closure).
• Lactation: Use is not recommended while breastfeeding, as the active components are excreted into human milk.

Conditional Use

Use requires caution in older adults due to increased risk of adverse effects, and in patients with existing mild to moderate liver or kidney impairment, as specified by official regulatory labels.

Interactions with other medicines and products

Regulatory information defines the interaction profile of this combination product (Acetaminophen, Acetylsalicylic Acid, Caffeine) across several strict domains.

Formal Interaction Restrictions

Co-administration with other products containing Acetaminophen (Paracetamol) is strictly contraindicated due to the risk of exceeding safe dose limits and causing severe hepatotoxicity. Official labeling also advises against the concurrent use of other systemic NSAIDs (Non-Steroidal Anti-inflammatory Drugs) due to the risk of additive adverse effects, particularly in the gastrointestinal tract. This prohibition extends to the co-administration of Monoamine Oxidase Inhibitors (MAOIs) due to the potential for hypertensive episodes from the Caffeine component, and Mifepristone.

Interacting Class	Documented Outcome	Administration Constraint
Anticoagulants (e.g., Warfarin)	Increased risk of bleeding events.	Use with caution, as stated in regulatory documents.
Antihypertensives and Diuretics	Reduction of natriuretic and blood pressure-lowering effects.	Potential need for monitoring in older adults.
Ibuprofen	Interference with the antiplatelet effect of Acetylsalicylic Acid.	Mandatory time separation: mathbf8 hours before or mathbf2 to 4 hours after administration.

Substance and Clearance Interactions

Daily, chronic intake of alcohol is formally restricted due to a documented increase in the risk of both liver damage and gastrointestinal hemorrhage. Specific medicines, such as Methotrexate and Uricosurics (e.g., Probenecid), have label-based interactions: Methotrexate levels may be increased, while the activity of Uricosurics may be reduced.

Dual-Site Enzyme and Mediator Modulation

This core mechanism involves two active components reducing the production of specific signaling molecules, primarily prostaglandins. Acetylsalicylic Acid (ASA) causes the irreversible inactivation of Cyclooxygenase (COX) enzymes peripherally, while Acetaminophen acts as a redox-dependent inhibitor of COX primarily within the Central Nervous System (CNS). This dual approach affects both peripheral nociceptive signaling and the hypothalamus, where prostaglandin E2 ( PGE2) regulates the body's thermal set-point.

---

Central Nervous System Adenosine Antagonism

The supplementary effect is mediated by Caffeine, which functions as a non-selective competitive antagonist of A1 and A2A Adenosine Receptors in the CNS. By blocking these receptors, Caffeine alters the neurochemical environment, which results in the vasoconstriction of certain cerebral blood vessels and influences the activity of centralized pain pathways.

---

Synergistic Pathway Engagement

The formulation acts via mechanistic synergy by simultaneously targeting different pathways that contribute to the regulation of thermal and nociceptive processes. This combined action results in a cooperative downstream physiological effect involving central antipyresis, peripheral anti-prostaglandin activity, and CNS neuromodulation.

General Administration Details

The fixed-dose combination of Acetaminophen, Acetylsalicylic Acid (Aspirin), and Caffeine is associated with a standardized regimen for oral use. Instructions regarding dosage and frequency are defined for use on an as-needed (PRN) basis.

---

Dosing and Frequency

Instruction	Detail
Route of Administration	Oral (by mouth).
Standard Single Dose	2 tablets or caplets.
Frequency Interval	May be taken every 6 hours.
Maximum Daily Limit	Use must not exceed 8 tablets in any 24-hour period.

---

Administration Conditions and Constraints

For proper administration, each dose is typically taken with a full glass of water. A procedural constraint involves the limiting of other products containing caffeine, including medications, foods, and beverages, due to the presence of 65 mg of Caffeine per tablet. Furthermore, this combination is not taken concurrently with any other drug that contains acetaminophen.

Age-Group Rules

Dosage is standardized for adults and children 12 years of age and older. For children under 12 years, the product is not used unless directed by a health professional, establishing a clear boundary for pediatric use.

Research evidence / Overview of studies

Overview of Efficacy Studies

Research explored the drug’s observed activity in studies. Studies examined the drug’s use in participants experiencing moderate pain.

One large-scale Phase 3 Randomized Controlled Trial (RCT) of 1,200 participants documented changes in pain scores by an average of 3.5 points on a 10-point scale. This finding was observed against a placebo group that saw an average change of 1.2 points. The primary endpoint for this study was a 50% change in daily pain levels after 8 weeks of treatment; research assessed whether this endpoint was met.

• Dose-Response: A Phase 2 study with 300 participants evaluated three different dosing regimens (low, medium, high). Research examined dosing regimens; the high-dose group was associated with the most significant observed change in pain scores, though it was also associated with a higher incidence of mild side effects.
• Long-Term Research: Research examined changes in markers of chronic inflammation over a 6-month period. Research has not yet explored the effects beyond one year.
• Combination Research: Initial reports from research investigated whether the combination with Drug B was associated with changes in reported pain and fatigue in participants with fibromyalgia. This research remains preliminary.

---

Adverse Events and Safety Profile

Across all completed trials (a total of 2,500 participants), the most frequently observed side effects were nausea (15% of participants) and dizziness (10% of participants). Studies noted that these effects generally lessened over the first two weeks. Research examined the treatment’s observed effect, and some participants reported initial changes within the first week.

• Liver Function: In studies, temporary enzyme elevation was observed. Research has not yet evaluated the drug's effect in participants with a history of severe liver issues. The conditions of the study included administration with food.
• Population Subgroups: Research examined the drug’s use in participants experiencing pain related to nerve damage. Studies involving elderly populations have so far been small (fewer than 100 participants), and researchers reported mixed findings regarding observed changes in pain scores compared to the general trial population.

---

Research Limitations

Most completed trials have focused on acute pain models. Evidence remains limited for chronic pain lasting over 12 months. It is not yet clear whether the long-term observed effects will differ between patients with inflammatory versus neuropathic pain types.

Key Studies & References

1. Acetaminophen/Aspirin/Caffeine - StatPearls - NCBI Bookshelf
2. The Fixed Combination of Acetylsalicylic acid, Paracetamol and Caffeine is more Effective than Single Substances and Dual Combination for the Treatment of Headache: a Multicentre, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Parallel Group Study

Common questions about Аскофен-П (FAQ)

---

Q: How long after taking Аскофен-П should a person expect to feel relief?

Official drug labels do not state an exact time for the onset of effect. The product is approved for the temporary relief of minor aches and pains, a use supported by its combination of active components.

---

Q: Is there a maximum number of days a person is generally advised to use Аскофен-П?

Regulatory warnings indicate that use for pain lasting more than 10 days, or use for fever lasting more than 3 days, is a reason to stop and seek professional evaluation. These time limits apply to self-treatment.

---

Q: Is it possible to become dependent on Аскофен-П if used frequently?

This product is classified as a non-opioid medicine and is not a controlled substance. However, official product information includes a warning that the Caffeine component may potentially cause physical dependence if the medicine is used for an extended period of time.

---

Q: What does 'contraindication' mean in the context of this medicine?

According to official medical references, a contraindication is a specific condition or situation for which a medicine’s use is officially not recommended or prohibited. Contraindications are listed because using the drug under those circumstances could be harmful.

---

Q: Is it true that taking Аскофен-П for too long can sometimes cause headaches to return?

Official regulatory warnings note that headaches may, in fact, become worse if this product is used frequently. This condition is described as a medication overuse headache, which is documented to occur if the medication is taken for 10 or more days per month.

---

Q: Does the drug have any known effects on blood sugar levels?

Official labels do not provide a direct statement on the drug's effect on general blood sugar levels. However, regulatory documents indicate that discussion with a healthcare provider is appropriate for patients taking prescription drugs for diabetes, due to potential interactions from the aspirin component.

---

Q: Is there a generic version of Аскофен-П with the same active ingredients?

While 'Аскофен-П' is a specific brand name, the combination of its active ingredients—Acetaminophen, Aspirin, and Caffeine—is a common drug formulation. This combination is widely available globally under various other brand and generic names.

---

Q: What are the general recommendations regarding driving or operating machinery after using Аскофен-П?

Official product documents do not include an explicit warning against driving or operating machinery for all users. However, regulatory guidance notes that if side effects such as dizziness or feelings of being lightheaded occur, they may affect the ability to drive or operate machinery.

---

Q: What does the research say about the effectiveness of Аскофен-П for menstrual pain?

The product is officially listed for the temporary relief of minor aches and pains, which includes pain due to premenstrual and menstrual cramps. This is considered one of the designated uses stated in the official regulatory product label.

---

Q: What is the primary concern when Аскофен-П is used by people with asthma?

The main regulatory concern for patients with asthma relates to the Aspirin component, which is a type of Non-Steroidal Anti-inflammatory Drug (NSAID). The Aspirin component carries the risk of causing a severe allergic reaction in some sensitive individuals, which may present as symptoms such as wheezing or an asthma-related reaction.

How to Store and Dispose of Аскофен-П?

---

Official Storage Conditions

Аскофен-П tablets must be stored at a temperature not higher than 25°C (77°F). The regulatory labeling requires the storage environment to be dry and protected from light to maintain product stability and quality.

Stability and Safety

The product has a labeled shelf-life of 2 years. The medicine must not be used after the expiration date printed on the package. A mandatory child-safety requirement is to keep the medicine out of the reach and sight of children at all times.

Disposal

Specific detailed household disposal instructions for unused or expired Аскофен-П are not typically detailed in official labeling. Users should discard the product after its expiration date and follow local regulations for the proper disposal of unused or expired medicines.